theranostika

Theranostika is a medical technique that combines a diagnostic test and a therapeutic treatment in a single step. The term "theranostics" is derived from the Greek words "therapeia," meaning treatment, and "gnosis," meaning knowledge.

In traditional medicine, a diagnostic test is performed to determine the presence and extent of a disease or condition, and a separate treatment is administered to manage or cure the disease. Theranostika, on the other hand, uses a single probe or biomarker to both diagnose and treat a disease.

Theranostika is primarily used in the field of nuclear medicine, particularly in the treatment of cancer. One common application of theranostika is in the imaging of prostate cancer. A single diagnostic agent, such as ^{177} Lu-labeled D Kotamide, is used to both diagnose the presence of cancer and deliver a therapeutic dose of radiation specific to the diseased cells.

The advantages of theranostika include improved accuracy and reduced toxicity. Since the diagnostic agent and therapeutic agent are linked together in the probe, the risk of off-target effects is minimized. Additionally, the theranostic agent can be designed to maximize specificity for diseased cells, reducing the overall dose required to achieve the desired therapeutic effect.

Research in theranostics is ongoing, with a focus on expanding applications to other disease states and improving the design and delivery of theranostic agents.